Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics
The publication, “Extracorporeal Ultrafiltration for Acute Heart Failure,” featured in
- Predictable, adjustable, and more efficient fluid removal with ultrafiltration compared to diuretics, without clinically adverse impact on renal function, leads to a reduction in hospital readmissions and financial burden;
- Applicability of ultrafiltration therapy in other clinical settings, such as cardiac surgery, burn and other specialty units, where active and prompt volume management is of utmost importance; and
- Expansion of use of ultrafiltration into outpatient centers and other ambulatory settings.
“We are excited to add this peer-reviewed analysis of ultrafiltration trials to our growing body of clinical evidence, which we are leveraging to change practice guidelines to make Aquadex the standard of care for fluid overload and increase its use across multiple specialty units in hospitals and outpatient centers,” said
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2023 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
1 Kazory A, Sgarabotto L, Ronco C: Extracorporeal Ultrafiltration for Acute Heart Failure. Cardiorenal Med 2023;13:1-8. doi: 10.1159/000527204
Source: Nuwellis, Inc.